ArticleIn vivo (Athens, Greece)
Clinical Implementation Gap of Comprehensive Genomic Profiling in Pancreatic Cancer: A Real-world Study.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimComprehensive genomic profiling (CGP) is increasingly used in pancreatic ductal adenocarcinoma (PDAC), yet its real-world clinical impact remains unclear. This study aimed to evaluate stepwise attrition from genomic detection to treatment implementation in routine practice. PATIENTS AND
methodsWe conducted a retrospective single-institution study of consecutive patients with PDAC who underwent CGP. Stepwise attrition was assessed across genomic detection, expert panel recommendation, and treatment execution. Clinical characteristics and exploratory overall survival (OS) were analyzed.
resultsAmong 57 patients, five (8.8%) harbored potentially actionable genomic alterations, whereas only two (3.5%) ultimately received genotype-matched therapy. Attrition was primarily attributable to regulatory and companion diagnostic constraints rather than clinical deterioration, as most patients had preserved performance status at CGP (ECOG 0-1: 91.2%). The median interval from diagnosis to CGP was 259 days. No significant difference in OS was observed between patients with and without CGP-attributed clinical impact (log-rank
conclusionIn PDAC, actionable genomic alterations were identified in 8.8% of patients, yet only 3.5% received genotype-matched therapy. These findings indicate that the clinical impact of CGP is limited primarily by implementation barriers rather than genomic detection itself. Earlier integration of CGP and improved access to matched therapies may enhance its real-world utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.